Insights Into Breast Cancer

Perspectives on current treatment practices regarding therapy of HR+, HER2+, and triple-negative advanced breast cancer, and attitudes toward recently introduced and upcoming agents in relapsed/refractory disease

Central – March 24, 2022

Faculty Chair

William Gradishar, MD, FACP

Center for Women’s Cancer Care

Southwest – March 30, 2022

Faculty Chair

Mark Pegram, MD

Stanford Women’s Cancer Center

Southeast – May 2, 2022

Faculty Chair

Reshma Mahtani, DO

University of Miami Health System

National – July 7, 2022

Faculty Chair

Adam Brufsky, MD, PhD

UPMC Hillman Cancer Center

Northeast – August, 2022

Faculty Chair

TBC

TBC

Midwest – September, 2022

Faculty Chair

TBC

TBC

Northwest – November, 2022

Faculty Chair

TBC

TBC

More Information

  • Virtual series
  • Southern California, Nevada, Utah, Arizona, New Mexico, Colorado

More Information

  • Virtual series
  • Kansas, Oklahoma, Texas, Missouri, Arkansas, Louisiana

More Information

  • Virtual series
  • Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia

More Information

  • Virtual series
  • National

More Information

  • Philadelphia, PA
  • Connecticut, Delaware, DC, Maine, Massachusetts, Maryland, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont

More Information

  • Chicago, IL
  • Illinois, Iowa, Nebraska, North Dakota, South Dakota, Wisconsin, Michigan, Indiana, Ohio

More Information

  • Portland, OR
  • Northern California, Oregon, Washington, Idaho, Montana, Wyoming

Example Agenda

Export meeting topics

View Agenda

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A virtual, moderated roundtable discussion focusing on the treatment of breast cancer
  • Disease state and data presentations are developed in conjunction with a national or regional oncology expert
  • Insights on the following therapies will be obtained
    • HR+: fulvestrant, letrozole, AIs, CDK4/6 inhibitors, PI3K and mTOR inhibitors, chemotherapies
    • HER2+: trastuzumab (and potential biosimilars), lapatinib, pertuzumab, T-DM1, trastuzumab deruxtecan, tucatinib, neratinib, AIs, chemotherapies
    • TNBC: PARP inhibitors, pembrolizumab, enzalutamide, antibody-drug conjugates (sacituzumab govitecan), immunotherapy, chemotherapies

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection is accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprises 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.